Gleason Score Articles & Analysis

3 news found

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

High-risk disease was defined using the LATITUDE criteria, which includes ≥2 risk factors: a Gleason score of ≥8, ≥3 bone lesions, and the presence of measurable visceral metastasis. ...

Feb. 16, 2023

ByBayer AG

Cleveland Diagnostics Announces Inclusion of IsoPSA in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

The NCCN panel now recommends the use of IsoPSA as an option to further define the probability of high-grade prostate cancer (Gleason score ≥ 3+4, Grade Group 2 or higher) prior to a first biopsy or after a negative biopsy. ...

May 11, 2022

ByCleveland Diagnostics, Inc.

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy

Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 ...

Jan. 18, 2022

ByProfound Medical Corp.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you